Nirmatrelvir/Ritonavir Reduced Severe COVID-19 Outcomes in High-Risk Adults With Preexisting Immunity
A pooled analysis of randomized trials shows nirmatrelvir/ritonavir significantly reduced hospitalizations and severe symptoms in high-risk COVID-19 patients with preexisting ...




